SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing immunotherapeutic human antibodies. The company applies advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce human antibodies targeted at specific diseases, including infectious diseases, such as COVID-19 and influenza; immune system disorders, including type 1 diabetes and organ transplantation; and cancer. Its DiversitAb platform is applicable to a range of human diseases. The company was founded in 2014 and is headquartered in Sioux Falls, South Dakota. The company trades on NGM exchange. The company headquarter is located in Sioux Falls ,United States.

TickerSABS
Long NameSAB Biotherapeutics, Inc.
Short NameSAB Biotherapeutics, Inc.